Tuberous Sclerosis — SCE Dermatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — mTOR (TSC1/TSC2) pathway
Tuberous sclerosis complex (TSC) is caused by mutations in TSC1 (hamartin) or TSC2 (tuberin) genes, which normally inhibit the mechanistic target of rapamycin (mTOR) pathway. Loss of function leads to constitutive mTOR activation and unregulated cell growth, causing hamartomas in multiple organs (brain, skin, kidneys, heart, lungs). Cutaneous features include ash leaf spots (earliest sign, visible under Wood lamp), facial angiofibromas, shagreen patches, periungual fibromas (Koenen tumours), and confetti-like hypopigmentation. Topical Sirolimus (mTOR inhibitor) is effective for facial angiofibromas.
Reference: BAD 2019; TSC International Consensus 2021